Recent evidence suggests that diabetic patients are resistant or partially responsive to treatments with a dual antiplatelet effect (especially clopidogrel) which is related to poor clinical outcomes such as stent thrombosis and recurrent atherothrombotic events.
3)4) Yang et al. 5) previously reported that triple antiplatelet therapy (dual antiplatelet plus cilostazol) results in more potent inhibition of adenosine diphosphase (ADP) induced platelet aggregation than dual antiplatelet therapy in patients with diabetes and drug-eluting stent (DES) implantation. These results suggest that triple antiplatelet therapy is a treatment option for amelioration of low responsiveness to clopidogrel in diabetes mellitus (DM).
No treatments of clopidogrel low responsiveness in DM have been reported to date. An initial approach to clopidogrel low responsiveness was considered to be a correctable cause of resistance, including hyperglycemia, noncompliance, insulin resistance (metabolic syndrome) and drug interaction.
Currently, practical strategies to overcome clopidogrel low responsiveness include 1) addition of cilostazol, 2) increasing the dose of antiplatelet agents, and 3) the use of new drugs, such as prasugrel or ticagrelor.
Adding Cilostazol
Cilostazol is a potent oral antiplatelet agent with a rapid onset of action that selectively inhibits phosphodiesterase III and increases cyclic adenosine mono phosphate (cAMP) levels in platelets. The increase in cAMP blocks all activating pathways in platelets, including ADP-induced platelet activations. 6) An OPTIMUS-2 study 7) of randomized crossover platelet function study in patients with type 2 DM and coronary artery disease following dual antiplatelet therapy revealed that the reduced platelet inhibition of P 2 Y 12 signaling can be enhanced by adjunctive treatment with cilostazol when compared with dual antiplatelet therapy. Thus, cilostazol led to significantly increased P 2 Y 12 platelet inhibition, as measured by flow cytometry and light transmission aggregometry. These findings were similar to the results of a study conducted by Yang et al. Several clinical studies have shown that triple antiplatelet therapy has better clinical outcomes than dual antiplatelet therapy in patients undergoing PCI and coronary stenting.
Lee et al. 8) compared the clinical benefit undergoing PCI between dual antiplatelet therapy (aspirin plus clopidogrel or ticlopidine, group I, n=1,597) and triple antiplatelet therapy (aspirin plus clopidogrel or ticlopidine plus cilostazol, group II, n=1,415) groups. They found that stent thrombosis within 30 days was significantly lower in group II (0.1%) than in group I (0.5%; p=0.024). Additionally, the independent predictors of stent throm-bosis were found to be primary stenting {hazard ratio (HR) 7.9, 95% confidence interval (CI) 2.0 to 30.8, p= 0.003} and triple therapy (HR 0.12, 95% CI 0.015 to 0.98, p=0.048). They concluded that triple antiplatelet therapy more effectively prevented thrombotic complications after stenting without an increased risk of side effects when compared to dual antiplatelet. These bench and clinical data indicated that adjunctive treatment with cilostazol may improve platelet inhibition in diabetic patients.
Increasing Dose of Clopidogrel
A recent study was conducted to evaluate the efficiency of an 150 mg oral maintenance dose of clopidogrel. 9) Sixty patients that were pre-treated with 600 mg of clopidogrel and had a successful PCI after 12 hours were included in this trial. The patients were divided into groups that received one of two clopidogrel daily maintenance doses (75 or 150 mg) for 30 days in a double-blind randomized manner. Platelet function was evaluated 30 days after intervention by optical aggregometry and a VerifyNow P 2 Y 12 assay. Administration of an 150 mg oral maintenance dose of clopidogrel resulted in more intense inhibition of platelet aggregation than administration of the currently recommended 75 mg maintenance dose. An OPTIMUS study selectively examined type 2 DM 10) and found that the use of a large maintenance dose resulted in higher platelet inhibition than the 75 mg clopidogrel maintenance dose. Large scale clinical data (CURRENT/OASIS 7) was recently presented at the European Society of Cardiology (ESC) 2009 meeting. These data indicated that doubling the loading and maintenance doses of clopidogrel used to treat patients with acute coronary syndrome undergoing PCI significantly reduced stent thrombosis and cardiovascular events without inducing a significant increase in major bleeding. These data suggest that increasing the dose of clopidogrel may ensure an adequate platelet response.
Use of New Thienopyridines
Additional agents that might be potential alternatives to overcome the low responsiveness associated with clopidogrel such as pasugrel, 11) AZD 6140 (ticagrelor) 12) and cangrelor 13) are currently being evaluated in clinical trials.
Prasugrel is a new thienopyridine derivative that produces more potent platelet inhibition and a rapid onset of action that is associated with irreversible P 2 Y 12 receptor blockade. The latter properties of prasugrel may provide a superior alternative to clopidogrel, with less response variability and a decreased prevalence of non-responsiveness. Brandt et al. 11) compared the rate of onset, magnitude, and consistency of platelet inhibition after administration of prasugrel or clopidogrel to relate platelet inhibition to systemic exposure to each active metabolite. Inhibition of platelet aggregation after treatment with prasugrel was significantly higher (p<0.01) than after treatment with clopidogrel from 15 minutes through 24 hours due to ADP induced platelet aggregation. Moreover, the response to prasugrel was more consistent than the response to clopidogrel. These results suggest that treatment with 60 mg prasugrel results in more rapid, potent, and consistent inhibition of platelet function than treatment with 300 mg clopidogrel. A TRITON-TIMI 38 trial 14) compared the effects of prasugrel and clopidogrel in patients (n=13,608) with moderate to high risk acute coronary syndrome (ACS) who were undergoing PCI. A composite end point of death, myocardial infarction and stroke occurred in 12.1% of the clopidogrel group and 9.9% of the prasugrel group (HR: 0.81, p<0.001). However, major bleeding occurred in 1.8% of the clopidogrel group and 2.4% of the prasugrel group (HR 1.32, p=0.03).
Ticagrelor is an oral and reversible P 2 Y 12 receptor blocker that does not require hepatic conversion to an active metabolite and produces an overall superior ADPinduced platelet inhibition with less response variability than clopidogrel. Ticagrelor has fast onset and offset actions that may be advantageous in patients who have to undergo immediate surgery. 12) A PLATO trial (n= 18,624) was conducted to compare treatment with ticagrelor (180 mg loading dose followed by 90 mg twice daily) to treatment with clopidogrel (300 to 600 mg loading dose followed by 75 mg daily) for the prevention of cardiovascular events and the results were recently presented at the ESC 2009 meeting. The primary composite of death, myocardial infarction and stroke was found to be reduced from 11.7% to 9.8% (HR, 0.84 ; p<0.001). In addition, the total mortality was reduced from 5.9% to 4.5% (p<0.001). However, there was no difference in total major bleeding between the two groups (11.6% vs. 11.2% ; p=0.434).
Treatment with new thienopyridines instead of clopidogrel in patients with ACS or PCI may provide good results in cardiovascular disease (CVD) endpoints and potential alternatives to low responsiveness to clopidogrel.
